Effects of Niaoduqing granules on inflammatory response of diabetic kidney disease: A meta‑analysis
- Peipei Zhou
- Zhenning Hao
- Weilong Xu
- Jiangyi Yu
Affiliations: Department of Endocrinology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210000, P.R. China
- Published online on: September 6, 2023 https://doi.org/10.3892/etm.2023.12193
Copyright: © Zhou
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Diabetic kidney disease (DKD) is one of the most severe chronic microvascular complications of diabetes and the leading cause of end‑stage kidney disease worldwide. The mechanism of inflammation underlying DKD has been attracting attention over recent years, but effective therapeutic strategies have remained elusive. Niaoduqing (NDQ) granules are one of the most commonly used drugs for the treatment of DKD in China, and it has therapeutic effects against inflammation in DKD. Therefore, the aim of the present analysis was to evaluate the inflammatory response outcomes and safety of NDQ granules for the treatment of DKD. The following databases were searched from their inception to 31st of May 2023 to obtain published accounts of relevant randomized controlled trials: China National Knowledge Infrastructure, China Science and Technology Journal, Wanfang, The Chinese Biomedicine, PubMed, Web of Science and Cochrane Library. The ‘risk of bias’ evaluation tool produced by the Cochrane Collaboration Handbook was used for evaluating the quality, whereas Revman software (version 5.3) was used for meta‑analysis. In total, 16 studies were included into the present study according to criteria, with a total of 1,526 patients. Compared with those in the control group, the results of the meta‑analysis revealed that the combination of conventional treatment and NDQ granules may further decrease C‑reactive protein [standardized mean difference (SMD), ‑1.33; 95% confidence interval (CI), ‑1.76, ‑0.91; P<0.00001], TNF‑α (SMD, ‑1.90; 95% CI, ‑2.35,‑1.45; P<0.00001) and IL‑6 (SMD, ‑1.72; 95% CI, ‑2.52,‑0.91; P<0.0001) levels, whilst increasing the clinical effective rate (risk ratio, 1.22; 95% CI, 1.14,1.29; P<0.00001), in patients with DKD. In terms of safety, a total of 34 and 39 patients included in the intervention and in the control group, respectively, developed adverse reactions. Results from the present analysis suggest that NDQ granules may be beneficial in suppressing inflammation caused by DKD when used in combination with conventional treatment, potentially guiding future directions in clinical practice. However, further high‑quality studies are needed to confirm the anti‑inflammation response in the future.